Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-02 |
2024-03 |
-0.1 |
-0.09 |
0.01 |
10.00% |
2024-02-28 |
2023-12 |
-0.1 |
-0.09 |
0.01 |
10.00% |
2023-11-02 |
2023-09 |
-0.1 |
-0.08 |
0.02 |
20.00% |
2023-08-03 |
2023-06 |
-0.08 |
-0.09 |
-0.01 |
-12.50% |
2023-05-11 |
2023-03 |
-0.09 |
-0.07 |
0.02 |
22.22% |
2023-03-16 |
2022-12 |
-0.11 |
-0.1 |
0.01 |
9.09% |
Date |
Firm |
Action |
From |
To |
2023-09-11 |
Goldman Sachs |
Upgrade |
Neutral |
Buy |
2023-08-28 |
Wedbush |
Upgrade |
Outperform |
Outperform |
2023-08-03 |
Needham |
Upgrade |
Buy |
Buy |
2023-06-14 |
Needham |
Upgrade |
Buy |
Buy |
2023-06-04 |
Needham |
Upgrade |
Buy |
Buy |
2023-05-11 |
Wedbush |
Upgrade |
Outperform |
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2023-12-28 |
AGGARWAL GAURAV |
Director |
1.97K |
Stock Award(Grant) |
2023-02-07 |
BLOOM OLIVIA KYUSUK |
Chief Financial Officer |
74.59K |
Sale |
2023-01-12 |
EASTHAM KARIN |
Director |
109.05K |
Conversion of Exercise of derivative security |
2023-02-08 |
GRETHLEIN ANDREW J |
Chief Operating Officer |
0.00 |
Sale |
2023-06-29 |
KAPUR ANIL |
Officer |
60.78K |
Stock Award(Grant) |
2024-05-14 |
LAWLIS V. BRYAN |
Director |
0.00 |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
35.98M |
115.49M |
6.87% |
2023-06-29 |
RA Capital Management, L.P. |
31.54M |
101.26M |
6.03% |
2023-06-29 |
Vanguard Group Inc |
26.68M |
85.65M |
5.10% |
2023-06-29 |
Deep Track Capital, Lp |
24.17M |
77.59M |
4.62% |
2023-06-29 |
Tcg Crossover Management, Llc |
23.59M |
75.72M |
4.51% |
2023-06-29 |
NEA Management Company, LLC |
21.35M |
68.53M |
4.08% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
16.34M |
52.44M |
3.12% |
2023-08-30 |
iShares Russell 2000 ETF |
11.33M |
27.54M |
2.17% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
11.16M |
27.13M |
2.13% |
2023-06-29 |
Vanguard Extended Market Index Fund |
6.21M |
19.93M |
1.19% |
2023-07-30 |
Fidelity Small Cap Index Fund |
4.44M |
14.39M |
0.85% |
2023-08-30 |
Invesco ETF Tr-Invesco Dynamic Pharmaceuticals ETF |
4.34M |
10.56M |
0.83% |
Split |
Date |
1058 : 1000 |
2014-07-22 |